Skip to main content

Empfield James R.'s Form 4 filing

Xenon Pharmaceuticals Inc. (XENE) · filed Aug 16, 2022

Accession no.
0001209191-22-046017
Filed
Aug 16, 2022
Trade date
Aug 12, 2022
Filing delay
4 days
Rule 10b5-1 plan
Not on the form (before 2023)

This filing lists 5 non-derivative transactions and 2 derivative transactions. Open-market sales total $2.21M. It was filed 4 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Empfield James R.CIK 0001665430Officer (EVP, Drug Discovery)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Aug 12, 2022Common SharesMOption exerciseAcquired+20,000$3.10+$62,00030,000Direct
Aug 12, 2022Common SharesMOption exerciseAcquired+45,000$4.75+$213,75075,000Direct
Aug 12, 2022Common SharesFTax withholdingDisposed−7,257$38.02−$275,911.1467,743Direct
Aug 12, 2022Common SharesSSaleDisposed−35,868$38.08−$1,365,853.4431,875Direct
Aug 12, 2022Common SharesSSaleDisposed−21,875$38.68−$846,12510,000Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Aug 12, 2022Common SharesMOption exerciseDisposed−20,000$0.00$00Direct
Aug 12, 2022Common SharesMOption exerciseDisposed−45,000$0.00$00Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)